Table 1 Patient characteristics.
From: PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
Variables | Total | PD-L1 (−) | PD-L1 (+) | P value |
|---|---|---|---|---|
54 (80.6%) | 13 (19.4%) | |||
Age (Median) | 48 | 51 (38–73) | 45 (22–72) | |
Sex | 0.82 | |||
Male | 38 | 31 (81.6%) | 7 (18.4%) | |
Female | 29 | 23 (79.3%) | 6 (20.7%) | |
ECOG | 0.99 | |||
0 | 3 | 3 (100%) | 0 (0.0%) | |
1 | 36 | 28 (77.8%) | 8 (22.2%) | |
2 | 26 | 21 (80.8%) | 5 (19.2%) | |
Not available | 2 | 2 (100%) | 0 (0.0%) | |
Histologic variant | 0.22 | |||
Leiomyosarcoma | 18 | 15 (83.3%) | 3 (16.7%) | |
Undifferentiated pleomorphic sarcoma | 13 | 9 (69.2%) | 4 (30.8%) | |
Angiosarcoma | 8 | 5 (62.5%) | 3 (37.5%) | |
Synovial sarcoma | 6 | 6 (100%) | 0 (0.0%) | |
Myofibroblastic sarcoma | 6 | 5 (83.3%) | 1 (16.7%) | |
MPNST | 5 | 3 (60%) | 2 (40%) | |
Etc* | 11 | 11 (100%) | 0 (0.0%) | |
Primary site | 0.23 | |||
Abdomen/pelvis | 23 | 20 (87.0%) | 3 (13.0%) | |
Extremity | 22 | 19 (86.4%) | 3 (13.6%) | |
Thorax | 18 | 13 (72.2%) | 5 (27.8%) | |
Head/neck | 4 | 2 (50%) | 2 (50%) | |
FNCLCC grade | 0.36 | |||
I | 6 | 6 (100%) | 0 (0.0%) | |
II | 33 | 27 (81.8%) | 6 (19.2%) | |
III | 28 | 21 (75%) | 7 (25%) | |
Number of previous chemotherapy | 0.83 | |||
1 | 48 | 38 (79.2%) | 10 (20.8%) | |
2 | 18 | 15 (83.3%) | 3 (16.7%) | |
3 | 1 | 1 (100%) | 0 (0.0%) | |
Type of previous chemotherapy received | NA | |||
Doxorubicin monotherapy | 9 | 7 (77.8%) | 2 (22.2%) | |
Ifosfamide monotherapy | 3 | 2 (66.7%) | 1 (33.3%) | |
Paclitaxel | 4 | 3 (75.0%) | 1 (25.0%) | |
Doxorubicin combination | 33 | 28 (84.8%) | 5 (15.2%) | |
Ifosfamide combination | 4 | 3 (66.7%) | 1 (33.3%) | |
Cyclophosphamide based | 14 | 11 (78.6%) | 3 (21.4%) | |
Gemcitabine/docetaxel | 14 | 12 (85.7%) | 2 (14.3%) | |